Literature DB >> 16802281

Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study.

Sarah L Ball1, Anthony J Holland, Johnny Hon, Felicia A Huppert, Peter Treppner, Peter C Watson.   

Abstract

BACKGROUND: Research based on retrospective reports by carers suggests that the presentation of dementia in people with Down's syndrome may differ from that typical of Alzheimer's disease (AD) in the general population, with the earliest changes tending to be in personality or behaviour rather than in memory. This is the first long-term prospective study to test the hypothesis that such changes, which are more typical of dementia of frontal type (DFT) in the general population, mark the preclinical stage of AD in DS.
METHODS: A previously identified population sample of older people with DS, first assessed in 1994 and followed-up 18 months later, were reassessed after a further 5 years. This study focuses on the 55 individuals who took part in the second follow-up. Dementia diagnosis was made using the modified CAMDEX informant interview and neuropsychological assessment was undertaken using the CAMCOG. Progression in clinical presentation was examined and degree of cognitive decline over time (on the CAMCOG and derived measures of executive function (EF) and memory) was compared across groups based on diagnosis and age: AD, DFT, personality/behaviour changes insufficient for a diagnosis of DFT (PBC), no diagnosis <50 years and no diagnosis 50 + years.
RESULTS: Progression was observed from early changes in personality and behaviour to an increase in characteristics associated with frontal lobe dysfunction and/or a deterioration in memory, prior to the development of full AD. Individuals who met criteria for DFT were significantly more likely to progress to a diagnosis of AD over the following 5 years than those who did not and those with PBC were significantly more likely to progress to a more severe diagnosis (DFT or AD) than those without. In the 5 years prior to diagnosis, participants with PBC and DFT had shown a degree of global cognitive decline intermediate between those with no dementia and those with AD. Both these groups had shown a significant decline in EF but not in memory, while the AD group had shown significant decline on both measures, with a significantly greater degree of decline in memory. Older participants without informant reported changes showed a more generalised pattern of decline.
CONCLUSIONS: These findings confirm that the early presentation of AD in DS is characterized by prominent personality and behaviour changes, associated with executive dysfunction, providing support for the notion that the functions of the frontal lobes may be compromised early in the course of the disease in this population. This has important implications for the diagnosis, treatment and management of dementia in people with DS. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16802281     DOI: 10.1002/gps.1545

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  31 in total

1.  Dementia diagnostic criteria in Down syndrome.

Authors:  Rory Sheehan; Amanda Sinai; Nick Bass; Pippa Blatchford; Ingrid Bohnen; Simon Bonell; Ken Courtenay; Angela Hassiotis; Therese Markar; Jane McCarthy; Kamalika Mukherji; Asim Naeem; Dimitrios Paschos; Natalia Perez-Achiaga; Vijaya Sharma; David Thomas; Zuzana Walker; Andre Strydom
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian
Journal:  Neurobiol Aging       Date:  2017-06-02       Impact factor: 4.673

3.  Down syndrome with posterior cortical atrophy.

Authors:  Claire Boutoleau-Bretonnière; Amandine Pallardy
Journal:  BMJ Case Rep       Date:  2018-02-08

4.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

5.  Outcome Measures for Clinical Trials in Down Syndrome.

Authors:  Anna J Esbensen; Stephen R Hooper; Deborah Fidler; Sigan L Hartley; Jamie Edgin; Xavier Liogier d'Ardhuy; George Capone; Frances A Conners; Carolyn B Mervis; Leonard Abbeduto; Michael Rafii; Sharon J Krinsky-McHale; Tiina Urv
Journal:  Am J Intellect Dev Disabil       Date:  2017-05

Review 6.  Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms.

Authors:  Amelia J Anderson-Mooney; Frederick A Schmitt; Elizabeth Head; Ira T Lott; Kenneth M Heilman
Journal:  Brain Cogn       Date:  2016-02-27       Impact factor: 2.310

7.  Long-term impact of parental well-being on adult outcomes and dementia status in individuals with Down syndrome.

Authors:  Anna J Esbensen; Marsha R Mailick; Wayne Silverman
Journal:  Am J Intellect Dev Disabil       Date:  2013-07

8.  Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia.

Authors:  Malcolm B Dick; Eric Doran; Michael Phelan; Ira T Lott
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jul-Sep       Impact factor: 2.703

9.  Intellectual Disability, Mild Cognitive Impairment, and Risk for Dementia.

Authors:  Wayne P Silverman; Warren B Zigman; Sharon J Krinsky-McHale; Robert Ryan; Nicole Schupf
Journal:  J Policy Pract Intellect Disabil       Date:  2013-09-01

Review 10.  Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.

Authors:  Panagiotis Zis; Andre Strydom
Journal:  Free Radic Biol Med       Date:  2017-09-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.